112 related articles for article (PubMed ID: 26598951)
21. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
Miller AK; Dusing R; Meggison A; Aires D
J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
[TBL] [Abstract][Full Text] [Related]
22. [Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil].
Florin V; Vercambre-Darras S; Piette F; Mortier L
Ann Dermatol Venereol; 2008; 135(8-9):603-4. PubMed ID: 18789300
[No Abstract] [Full Text] [Related]
23. [Treatment of disseminated variants of skin melanoma].
Khachaturian LM; Murenkov OV
Vopr Onkol; 1981; 27(11):47-50. PubMed ID: 7336668
[No Abstract] [Full Text] [Related]
24. Using topical imiquimod for the management of positive in situ margins after melanoma resection.
Pandit AS; Geiger EJ; Ariyan S; Narayan D; Choi JN
Cancer Med; 2015 Apr; 4(4):507-12. PubMed ID: 25620351
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
26. Targeting Both Tumor and Stroma Cells to Treat Melanoma: NIPAWILMA.
Oncol Res Treat; 2016; 39(10):652-654. PubMed ID: 27710979
[No Abstract] [Full Text] [Related]
27. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Yeung C; Petrella TM; Wright FC; Abadir W; Look Hong NJ
Expert Rev Clin Immunol; 2017 Apr; 13(4):383-388. PubMed ID: 28121191
[TBL] [Abstract][Full Text] [Related]
28. The intralesional interleukin-2 is an adequate palliative treatment in cutaneous metastases of melanoma.
Menis D; Monsalvez-Honrubia V; Maroñas-Jiménez L; Morales-Raya C; Ortiz-Romero PL
G Ital Dermatol Venereol; 2017 Aug; 152(4):400-401. PubMed ID: 28621122
[No Abstract] [Full Text] [Related]
29. Treatment with β-blockers and reduced disease progression in patients with thick melanoma.
De Giorgi V; Grazzini M; Gandini S; Benemei S; Lotti T; Marchionni N; Geppetti P
Arch Intern Med; 2011 Apr; 171(8):779-81. PubMed ID: 21518948
[TBL] [Abstract][Full Text] [Related]
30. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up.
Vidal D; Matías-Guiu X; Alomar A
Arch Dermatol; 2007 Feb; 143(2):266-8. PubMed ID: 17310012
[No Abstract] [Full Text] [Related]
31. [Therapeutic planning and prognosis in cutaneous malignant melanoma].
Veronesi U; Cascinelli N; Preda F; Bastagli A
Arch Ital Chir; 1969; 95(5):607-27. PubMed ID: 5407514
[No Abstract] [Full Text] [Related]
32. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
Boyd KU; Wehrli BM; Temple CL
J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
[TBL] [Abstract][Full Text] [Related]
33. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
[TBL] [Abstract][Full Text] [Related]
34. Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy.
Heber G; Helbig D; Pönitzsch I; Wetzig T; Harth W; Simon JC
J Dtsch Dermatol Ges; 2009 Jun; 7(6):534-6. PubMed ID: 19250248
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis.
Pham JP; Dwyer L; Phan K; Menzies AM; Frew JW
Melanoma Res; 2023 Oct; 33(5):434-436. PubMed ID: 37650727
[No Abstract] [Full Text] [Related]
36. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of lymphatic invasion: intra-arterial chemotherapy and curettage].
Lasne E; Lodiot Y
Soins Chir; 1984; (42-43):15-7. PubMed ID: 6569625
[No Abstract] [Full Text] [Related]
39. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
40. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone.
Martiniuk F; Damian DL; Thompson JF; Scolyer RA; Tchou-Wong KM; Levis WR
J Drugs Dermatol; 2010 Nov; 9(11):1368-72. PubMed ID: 21061759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
